The global human microbiome market size was estimated at US$ 0.94 billion in 2024, projected to increase to US$ 1.23 billion in 2025 and reach US$ 13.87 billion by 2034, showing a healthy CAGR of 30.97% across the forecast years.
Growing R&D collaborations - Pharma, biotech, and academic institutions are expanding research and clinical trials.
Expansion of Microbiome Startups - Emerging biotech startups and collaborations are pushing innovation and commercialization.
Ongoing clinical trials are exploring how manipulating the human microbiome could help treat diverse diseases and support overall health.
Human microbiome patient support emphasizes educating people about gut health and offering resources to help maintain a balanced microbiome. This involves personalized nutrition guidance, access to scientific and clinical information, and tools that empower patients to actively participate in decisions regarding their healthcare.
Distribution of human microbiome products, such as therapeutics, diagnostics, and supplements like probiotics and prebiotics, is expanding to reach hospitals and pharmacies.
In April 2025, Metabolon introduced a combined metagenomics and metabolite panel aimed at simplifying microbiome research workflows. Dr. Karl Bradshaw, Chief Business Officer at Metabolon, stated, “Metabolon is now a one-stop solution for obtaining high-quality metagenomics and metabolomics data, integrated and visualized through an intuitive bioinformatics platform.” He added that this integration allows researchers to gain deeper insights into the microbiome than either method alone, emphasizing that metabolomics complements metagenomics by quickly revealing the biological effects of microbiome changes.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
